|Bid||163.46 x 800|
|Ask||163.94 x 800|
|Day's range||162.96 - 164.06|
|52-week range||133.65 - 179.92|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||24.47|
|Earnings date||19 Oct 2021|
|Forward dividend & yield||4.24 (2.59%)|
|Ex-dividend date||23 Aug 2021|
|1y target est||188.29|
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.